#Drug Safety
Explore articles tagged with Drug Safety
HRV Pharma Partners with Haleos Labs to Accelerate Orphan and Niche API Development
HRV Pharma has entered a multi‑year strategic partnership with Haleos Labs to accelerate the development and manufacture of orphan and niche APIs, strengthening global access to complex therapies for rare diseases.
How HRV Pharma’s Virtual Model Helps Solve America’s Drug Shortage Crisis
HRV Pharma’s capital‑efficient virtual pharmaceutical model is helping address America’s drug shortage crisis by linking underutilized global manufacturing capacity with regulatory strength to ensure consistent API supply.
HRV Pharma Redefines India’s Bulk Drug Business with a Virtual Pharma Model
Fortune India features HRV Pharma for pioneering a capital‑efficient virtual pharma model that is transforming India’s bulk drug and API ecosystem through speed, compliance, and global regulatory execution.
Pharma Safety, ESG and Virtual Manufacturing: Insights from Hari Kiran Chereddi
Workplace safety in pharma can no longer be a checklist exercise. This blog shares how HRV Pharma, led by MD & CEO Hari Kiran Chereddi, is using virtual manufacturing networks, stronger EHS governance, and ESG‑aligned practices to raise safety standards across partner sites and protect people, reputation, and India’s role as the world’s pharmacy.
Cheaper Obesity Drugs: Cure or Crisis for India?
HRV Pharma's CEO examines the implications of cheaper GLP-1 obesity drugs coming to India post-semaglutide patent expiry, highlighting both transformative potential and misuse risks requiring careful regulation.
From Volume to Value: India's Strategic API Leadership Evolution
HRV Global's Managing Director Hari Kiran Chereddi discusses India's transformation from volume-driven API supplier to value-oriented strategic partner, highlighting virtual pharma models and AI-driven operations.